Engineered immune cells take aim at debilitating autoimmune diseases

NCT ID NCT06939166

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, to calm overactive immune attacks in people with severe autoimmune diseases like multiple sclerosis, myasthenia gravis, and neuromyelitis optica. Up to 12 adults whose disease has returned or not responded to standard therapies will receive a single infusion of these 'off-the-shelf' donor cells. The main goal is to check safety and find the right dose, while also watching for any improvement in symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system autoimmune encephalitis chronic inflammatory demyelinating polyradiculoneuropathy multiple sclerosis myasthenia gravis neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tianjin Huanhu Hospital

    RECRUITING

    Tianjin, China

    Contact Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact